^
    Back
    Association details:
    Biomarker:ATM deletion
    Cancer:Solid Tumor
    Drug:elimusertib (BAY 1895344) (ATR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C2 – Inclusion Criteria
    Source:
    clinicaltrials.gov
    Title:

    First-in-human Study of ATR Inhibitor BAY1895344 in Patients With Advanced Solid Tumors and Lymphomas

    Excerpt:
    ...Patients with tumors known to be positive for deoxyribonucleic acid damage repair (DDR) defects (such as ataxia-telangiectasia mutated [ATM] deleterious mutation or low ATM expression) can be included....
    Trial ID:
    NCT03188965
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Cancer Discov
    Title:

    ATR Inhibition as an Attractive Therapeutic Resource against Cancer

    Excerpt:
    ...BAY 1895344, a new potent and specific ATR inhibitor, is safe and able to induce durable responses in ATM-deficient tumors.
    DOI:
    10.1158/2159-8290.CD-20-1354